Market research
SLDB Solid Biosciences LLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 982M
- P/E ratio
- Not available
- Analyst target
- 17.8333
- Dividend yield
- Not available
- Beta
- 2.42
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US83422E2046
- Market cap
- 982M
- P/E ratio
- Not available
- Analyst target
- 17.8333
- Dividend yield
- Not available
- Beta
- 2.42
About
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SLDB discussion.
5 years, 4 months ago
Solid Biosciences Inc is currently in a long term downtrend where the price is trading 34.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Solid Biosciences Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 32.9% to $-21M since the same quarter in the previous year.
Finally, its free cash flow grew by 105.7% to $1M since the same quarter in the previous year.
Based on the above factors, Solid Biosciences Inc gets an overall score of 3/5.